Important note: Information in this article was accurate in 2003. The state of the art may have changed since the publication date.AIDS Community Research Initiative of America (ACRIA) - Winter 2002/2003
Liz Highleyman
|
Experimental drug candidates are usually designated by a combination of letters and numbers. The letters typically stand for the drug company that discovered or first began developing the agent; for instance, T-1249 is being developed by Trimeris. Mergers and sales make matters more confusing. For example, “DPC” agents are owned by Bristol-Myers Squibb, which acquired DuPont, and “AG” candidates were first developed by Agouron, which is now part of Pfizer. As a drug nears the end of the development pipeline, it is given a generic name and later a brand name for marketing. To confuse things further, some drugs - especially nucleoside analogs - also have chemical names such as FTC or FddA. |
20030101
CR030109
Copyright © 2003 - AIDS Community Research Initiative of America. Reproduction of this article (other than one copy for personal reference) must be cleared through the Editor, ACRIA Update, 230 West 38th Street, 17th Floor, New York, NY 10018; (212) 924-3934; Fax (212) 924-3936 .
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. ÆGIS. All materials appearing on ÆGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGIS, or the party credited as the provider of the content.